Xeljanz (Tofacitinib) Rheumatoid Arthritis Commercial

Xeljanz TV commercial puts new kick in RA ads? “Arms were made for hugging. Hands for holding. Feet, kicking. Better things than the joint pain and swelling of moderate to severe Rheumatoid Arthritis.” So begins the new Xeljanz direct to consumer TV ad. It’s rather different from the other Rheumatoid Arthritis drug commercials: It is black and...Continue reading      50 Comments » Read more

Efficacy of Xeljanz, Biologics, & DMARDs in Rheumatoid Disease

Why should I feel like I failed? I’m not alone We probably agree it’s unfair to say, “patients fail treatments” instead of the reverse, but there is still disappointment. I was optimistic that my Rheumatoid disease would respond to Xeljanz, the new oral DMARD (disease modifying anti-rheumatic drug) from Pfizer. Unfortunately, my joint stiffness and inflammation,...Continue reading      44 Comments » Read more

Xeljanz Rejected by European Medicines Agency

EMA rejects Xeljanz authorization Late yesterday, the European Medicines Agency (EMA) rejected the Pfizer’s application to market Xeljanz (tofacitinib). The EMA application was refused because the Committee for Medicinal Products for Human Use (CHMP) “adopted a negative opinion” on approving Xeljanz, stating they were unconvinced its risks outweighed benefits. Last November, the FDA approved the 5mg...Continue reading      29 Comments » Read more

Xeljanz Cost with a Copay Card, Free Samples, Efficacy, & Side Effects: Gathering Rheumatoid Arthritis Patient Stories

Please share your experiences with Xeljanz on the comments page here. Patient stories are starting to come in across the blog and I thought this would be more convenient for others searching for answers. Here’s my story. A copay card for the newly approved DMARD, Xeljanz Two years ago, my rheumatologist recommended I “just wait for something...Continue reading      135 Comments » Read more

Rheumatoid Arthritis Drug Approved by US FDA: Pfizer’s Xeljanz Pill (Tofacitinib)

For over two and a half years, we’ve followed Pfizer’s tofacitinib through clinical trials for FDA approval. Today, the U.S. FDA approved the new drug that will be called Xeljanz. Click here to read the full Pfizer press release for Xeljanz.   The first JAK for Rheumatoid Arthritis approved: “Xeljanz” The U.S. Food and Drug Administration (FDA) announced...Continue reading      35 Comments » Read more

Pfizer’s Rheumatoid Arthritis Pill Approved by Food and Drug Administration (FDA)

Note: Click here to read more about Xeljanz, the first new oral medication for Rheumatoid Arthritis in 10 years, and a short list of questions and answers for patients. Sign up for regular blog updates by email to watch for more updates on this new treatment and others. Pfizer press release about Xeljanz NEW YORK--(BUSINESS WIRE)--Pfizer...Continue reading      7 Comments » Read more

RA News: Pfizer Pill Beats Methotrexate, Alcohol Reduces RA Risk, Periodontal Disease High

Pfizer oral JAK “superior” to methotrexate Pfizer released a statement about their two year study, ORAL Start, which puts their new oral JAK treatment for Rheumatoid Arthritis directly up against methotrexate.  The oral medication, currently called tofacitinib, is taken twice daily in either 5 or 10 mg doses. “Tofacitinib was found to be superior to MTX...Continue reading      9 Comments » Read more

Mind-boggling! – Aftermath of Tofacitinib FDA Hearing Part 2

After the FDA Arthritis Advisory Committee (AAC) hearing earlier this month for Pfizer’s new oral treatment for RA,  tofacitinib, we looked at the four distinct votes of the AAC and some of the ways the media responded to them. They ranged from serious to pitiful to laughable. But there’s more.     3 news bytes that might...Continue reading      14 Comments » Read more

Aftermath of the FDA Vote on Pfizer’s RA JAK Inhibitor, Tofacitinib

After the tofacitinib FDA hearing, the votes are in, false perceptions persist, and patients still need relief. Some estimate that tofacitinib could be approved by the US FDA within a few months after mixed votes and mostly inaccurate press reports. It’s fitting this discussion takes place as rawarrior.com begins its fourth year of reporting the patient...Continue reading      44 Comments » Read more

FDA Arthritis Advisory Committee Hearing for Pfizer’s RA JAK: Tofacitinb

Advisory Committee hearing feed link My daughter Katie Beth and I are in Washington, DC for the final FDA Arthritis Advisory Committee (AAC) hearing about Pfizer’s JAK, tofacitinib. Early in the morning, Katie Beth and I will be en route to the meeting. The AAC meeting will be broadcast online with a live feed. We’ve been told...Continue reading      27 Comments » Read more

Attending an FDA Hearing for Pfizer’s JAK: Tofacitinib CP-690550

Three years ago, one of the first friends I made through my blog was Angie. She got into a Pfizer clinical trial for tofacitinib (then called tasocitinib). She sent me some info about the trial, but my rheum doc wasn’t interested and I didn’t pursue it. The current excitement about Pfizer’s tofacitinib Tofacitinib is an oral medication...Continue reading      28 Comments » Read more

Pfizer’s JAK inhibitor Tofacitinib EMA Application Validated

Pfizer JAK-3 press release “Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis: Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by...Continue reading      10 Comments » Read more

    Welcome to RA Warrior!


    Thanks for visiting this unique site full of information and encouragement to fight Rheumatoid Disease. You'll find hope, humor, and a helpful online community. I'm Kelly & I'll be glad to show you around if you'll click right here.


    View more gifts at Zazzle.

    Let's Pin Together!

Would You Like Free Email Updates?
Stay in touch with RA Warrior.
We respect your privacy. Your email address will never be shared.